Literature DB >> 32272301

Exosome-mimetics as an engineered gene-activated matrix induces in-situ vascularized osteogenesis.

Yao Zha1, Tianyi Lin2, Yawu Li1, Xin Zhang1, Zihao Wang1, Zubing Li2, Yongqin Ye3, Bin Wang3, Shengmin Zhang1, Jianglin Wang4.   

Abstract

Exosome has been considered as an instructive supplement between complicated cell therapy and single gene/protein drug treatment in the field of regenerative medicine due to its excellent biocompatibility, efficient cellular internalization and large loading capacity. Nevertheless, one major issue that extremely restricts the potential application as gene/drug vehicles is the low yield of nanoscale exosome. Moreover, the intravenous injection of targeted exosomes may cause the obstruction of blood-rich organs. Thus, herein we fabricated a specific exosome-mimetics (EMs) that could come true mass and fast production exhibited the similar size, morphology and membrane protein markers in comparison with conventional exosomes. To bypass the risk of intravenous injection and improve the efficiency of topical therapy, we simultaneously applied the engineered EMs to design a gene-activated matrix (GAM) that could be locally released by encapsulating the plasmid of vascular endothelial growth factor (VEGF) and flexibly binding onto a core-shell nanofiber film. Our findings showed that the well-designed engineered EMs-mediated GAM was able to sustainably deliver VEGF gene and significantly enhance the vascularized osteogenesis in vivo. The current work can not only consolidate the applied foundation of EMs through the breakthrough of high yield, but also provide a local and effective delivery of engineered EMs for the in-situ therapy.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Core-shell nanofiber; Exosome-mimetics; Gene-activated matrix; Osteogenesis

Mesh:

Substances:

Year:  2020        PMID: 32272301     DOI: 10.1016/j.biomaterials.2020.119985

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  7 in total

1.  Progenitor cell-derived exosomes endowed with VEGF plasmids enhance osteogenic induction and vascular remodeling in large segmental bone defects.

Authors:  Yao Zha; Yawu Li; Tianyi Lin; Jia Chen; Shengmin Zhang; Jianglin Wang
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

Review 2.  Bioactive Scaffolds Integrated with Liposomal or Extracellular Vesicles for Bone Regeneration.

Authors:  Minjee Kang; Chung-Sung Lee; Min Lee
Journal:  Bioengineering (Basel)       Date:  2021-10-01

3.  N-carboxymethyl chitosan/sodium alginate composite hydrogel loading plasmid DNA as a promising gene activated matrix for in-situ burn wound treatment.

Authors:  Litong Wang; Le Sun; Zhiyang Gu; Wenya Li; Lili Guo; Saibo Ma; Lan Guo; Wangwang Zhang; Baoqin Han; Jing Chang
Journal:  Bioact Mater       Date:  2021-12-20

Review 4.  Multiplexed strategies toward clinical translation of extracellular vesicles.

Authors:  Junying Song; Baoqiang Song; Lijun Yuan; Guodong Yang
Journal:  Theranostics       Date:  2022-09-21       Impact factor: 11.600

Review 5.  Emerging strategies in reprogramming and enhancing the fate of mesenchymal stem cells for bone and cartilage tissue engineering.

Authors:  Yu Seon Kim; Antonios G Mikos
Journal:  J Control Release       Date:  2020-12-31       Impact factor: 9.776

6.  Engineered versus hybrid cellular vesicles as efficient drug delivery systems: a comparative study with brain targeted vesicles.

Authors:  Maria Kannavou; Antonia Marazioti; Georgios T Stathopoulos; Sophia G Antimisiaris
Journal:  Drug Deliv Transl Res       Date:  2021-01-20       Impact factor: 4.617

Review 7.  Emerging role of exosomes in craniofacial and dental applications.

Authors:  Xin Xing; Shuang Han; Zhi Li; Zubing Li
Journal:  Theranostics       Date:  2020-07-09       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.